RON

RON Overview

English NameMacrophage-stimulating protein receptorApproved Drugs1
Drugs in Clinical Trials2Target SynonymRon tyrosine kinase receptor,MSP Receptor,PTK8,PTK8 Protein Tyrosine Kinase 8,Macrophage Stimulating 1 Receptor,MST1R,NPCA3,S13 Avian Erythroblastosis Oncogene Homolog,CDw136,CD136,CD136 Antigen,C-Met-Related Tyrosine Kinase,EC:2.7.10.1,EC 2.7.10.1,Protein-Tyrosine Kinase 8,S13 Erythroblastosis Oncogene Homolog,RON,SEA,Macrophage-Stimulating Protein Receptor,S13 Erythroblastosis (Avian) Oncogene Homolog,P185-Ron,EC 2.7.10
Highest Development StageApproved
English NameMacrophage-stimulating protein receptor
Target SynonymRon tyrosine kinase receptor,MSP Receptor,PTK8,PTK8 Protein Tyrosine Kinase 8,Macrophage Stimulating 1 Receptor,MST1R,NPCA3,S13 Avian Erythroblastosis Oncogene Homolog,CDw136,CD136,CD136 Antigen,C-Met-Related Tyrosine Kinase,EC:2.7.10.1,EC 2.7.10.1,Protein-Tyrosine Kinase 8,S13 Erythroblastosis Oncogene Homolog,RON,SEA,Macrophage-Stimulating Protein Receptor,S13 Erythroblastosis (Avian) Oncogene Homolog,P185-Ron,EC 2.7.10
Approved Drugs1
Drugs in Clinical Trials2
Highest Development StageApproved

RON Product List

  • Product Category

    Protein (1)

  • Product Status

    Launched (1)

  • Species

    Human (1)

  • Tag

    His Tag (1)

  • Conjugate

    Unconjugated (1)

Cat. No.SpeciesHostProduct DescriptionStructurePurityFeature
RON-H52H9
Human
HEK293
Human RON / MSPR Protein, His Tag (MALS verified)
Total: 1
  • 1

RON Background

Receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding to MST1 ligand. Regulates many physiological processes including cell survival, migration and differentiation. Ligand binding at the cell surface induces autophosphorylation of RON on its intracellular domain that provides docking sites for downstream signaling molecules. Following activation by ligand, interacts with the PI3-kinase subunit PIK3R1, PLCG1 or the adapter GAB1. Recruitment of these downstream effectors by RON leads to the activation of several signaling cascades including the RAS-ERK, PI3 kinase-AKT, or PLCgamma-PKC. RON signaling activates the wound healing response by promoting epithelial cell migration, proliferation as well as survival at the wound site. Plays also a role in the innate immune response by regulating the migration and phagocytic activity of macrophages. Alternatively, RON can also promote signals such as cell migration and proliferation in response to growth factors other than MST1 ligand.

RON Synonyms

CD136 antigen,CD136,CDw136c-met-related tyrosine kinase,EC 2.7.10,EC 2.7.10.1,macrophage stimulating 1 receptor (c-met-related tyrosine kinase),MSP R,MSP receptor,MSPR,MST1R,p185-Ron,Protein-tyrosine kinase 8,PTK8 protein tyrosine kinase 8,PTK8,Ron,RONmac

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
Ningetinib TosylateCT-053-PTSA; CT-053Phase 2 ClinicalHec Pharm Co LtdCarcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Intestinal Neoplasms; Leukemia, Myeloid, Acute; Lung Neoplasms; Solid tumours; Stomach Neoplasms
Details
Merestinib5OGS5K699E; LY-2801653Phase 2 ClinicalEli Lilly And CompanyBiliary Tract Neoplasms; Bone metastases; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Colorectal Neoplasms; Gallbladder Neoplasms; Leukemia, Myeloid, Acute; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Microsatellite instability-high cancer; Neoplasm Metastasis; Neoplasms; Pancreatic Neoplasms; Skin Melanoma; Solid tumours
Details

Marketed Drug Information

English NameResearch CodeHighest Development StageCompanyEarliest Brand NameEarliest Approval CountryEarliest IndicationEarliest Approval CompanyEarliest Approval DateIndicationClinical Trial
CrizotinibPF-1066; PF-2341066; PF-02341066; PF-002341066ApprovedPfizer Inc赛可瑞, XalkoriUnited StatesCarcinoma, Non-Small-Cell LungPf Prism Cv2011-08-26Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Granuloma, Plasma Cell; Hematologic Neoplasms; Lung Neoplasms; Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Primary Cutaneous Anaplastic Large Cell; Multiple Myeloma; Myofibroma; Neoplasm Metastasis; Neoplasms; Neurilemmoma; Neuroblastoma; Neurofibromatosis 2; Renal Insufficiency; Solid tumours; Ureteral Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uveal melanoma
Details
  • Overview
  • Product List
  • Marketed Drug Information
  • Clinical Drug Information